Histologic transformation from NSCLC to small cell lung cancer (SCLC) is a known mechanism of resistance to third-generation EGFR-TKIs, as well as to first-line osimertinib treatment [70]. The gene discussed is EGFR; the disease is small cell lung carcinoma.